DUBLIN, May 5, 2021 /PRNewswire/ -- Medtronic plc
(NYSE:MDT), the global leader in medical technology, today
announced CareGuidePro™, a mobile application and web portal that
serves as a virtual guide for patients throughout their Medtronic
spinal cord stimulation therapy journey. The patient's care team,
including physicians and Medtronic, may also use the CareGuidePro
platform to help manage and support the patient's experience with
spinal cord stimulation. Patients also have the ability to record
their pain relief and other feedback directly into the app,
providing detailed Patient Reported Outcomes (PROs) to ensure
timely, essential information is recorded and accessible even
outside of in-person office visits.
"Pain management is a complex and intensely personal experience
for individual patients. Every patient is a singular case. The
ability to monitor patients more closely, to receive data and
feedback more quickly, means we can adjust and adapt therapies more
efficiently and effectively when needed," said Krishnan Chakravarthy, M.D., Ph.D., a
San Diego-based interventional
pain management physician and first physician to use the technology
with patients. "This is an important step forward for the field of
neuromodulation and patient care."
"Knowledge is power, and digital health solutions like
CareGuidePro give patients the tools they need to ask the right
questions and make informed care decisions, which we know can lead
to better long-term outcomes," said Nandan
Lad, M.D., Ph.D., professor of neurosurgery at Duke University and co-founder of Higgs Boson
Health. "By providing patients with the right information at the
right time, we also aim to reduce inefficiencies and free up care
teams to focus on providing outstanding care."
"CareGuidePro is Medtronic's first patient-centric digital
health platform created for spinal cord stimulation patients,
intended as a seamless solution that will naturally integrate into
the care provider's workflow," said Dave
Anderson, president of the Neuromodulation business, which
is part of the Neuroscience Portfolio at Medtronic. "We believe
this digital health platform will facilitate a more informative and
engaging patient experience that will translate into better
physician-patient dialogue, potentially contributing to better
therapy management."
CareGuidePro features include:
- Caregiver access for patients less familiar or able to manage
the app, enabling easy access to essential information
- Procedure-specific FAQs and task lists/reminders
- Standardized and Custom Patient Reported Outcomes (PRO)
surveys
- Secure sharing of PROs to keep entire care team informed
- Secure, encrypted two-way communication and file-sharing
Medtronic is currently enrolling patients for the app's limited
commercial release, with a full United
States release expected in late summer. CareGuidePro is
available on iOS® and Android™ devices.
About Medtronic
Medtronic plc (www.medtronic.com),
headquartered in Dublin, Ireland,
is among the world's largest medical technology, services and
solutions companies – alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Android is a trademark of Google LLC. iOS is a registered
trademark of Cisco in the U.S. and is used by Apple under
license.
Contacts:
|
|
Jeff
Trauring
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-763-505-0159
|
+1-763-505-4626
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medtronic-announces-careguidepro-a-new-mobile-app-and-online-platform-for-patients-to-navigate-their-spinal-cord-stimulation-journey-301284002.html
SOURCE Medtronic plc